Wysa vs Nabla

Nabla has a disclosed valuation of $180M, while Wysa's valuation is not publicly available, making a direct size comparison difficult. Nabla employs 80 people.

Nabla has raised more in total funding at $30M, compared to Wysa's $30M — a gap of N/A. Combined, the two companies have completed 1 known funding rounds.

Nabla holds the higher Awaira Score at 73/100, compared to Wysa's 63/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 10-point gap that reflects meaningful differences in scale or traction.

Wysa was founded by Jo Aggarwal in 2015. Nabla was founded by Alexandre Lebrun in 2018. Visit each company's profile on Awaira for a full founder biography.

Wysa: Wysa is an AI mental health platform that provides evidence-based cognitive behavioral therapy techniques through a conversational AI chatbot, offering anonymous, stigma-free mental health support accessible via smartphone at any hour. The platform uses clinically validated CBT, DBT, and mindfulness exercises delivered conversationally, and provides a step-up pathway to licensed human therapists for users requiring more intensive support.\n\nThe company raised approximately $30M in Series B funding and has deployed its platform to over five million users globally, including through enterprise employee wellness programs, NHS partnerships in the UK, and healthcare system integrations in the United States and India. Wysa has published peer-reviewed clinical evidence demonstrating statistically significant improvements in depression and anxiety scores.\n\nMental health care access is a global crisis with a severe therapist shortage that AI can meaningfully address at the first-line support level. Wysa's combination of clinical validation, enterprise and payer relationships, and scalable AI delivery model positions it as one of the more credible players in the crowded digital mental health space. Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform leverages natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency.

Wysa was founded first in 2015, giving it 3 years of additional market experience. Nabla was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Wysa has approximately 50-200 employees, while Nabla has approximately 80. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Wysa and Nabla are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.